Collexis' BiomedExperts Rapidly Expanding its User Base

Collexis Holdings Inc, (OTCBB: CLXS) a leading developer of high definition search and knowledge discovery software, announced that its premier professional scientific social networking site, Biomedexperts.com, has more than 30,000 registered users, enabling researchers across organizations and around the globe to collaborate more efficiently and effectively.

In April Collexis implemented the first phase of their marketing campaign and since that time BiomedExperts' user registrations have skyrocketed from 2,000 to more than 30,000. BiomedExperts.com is a collaborative agreement with Dell Healthcare and Life Sciences. Through this initiative, Dell is providing the hardware and continued marketing support for the site and Collexis is contributing knowledge discovery and text mining applications.

"The success of BiomedExperts.com is a testament to the role innovative technology can play in enabling researchers to collaborate and drive meaningful scientific discoveries," said James Coffin, Ph.D., vice president and general manager, Dell Health Care and Life Sciences. "The possibilities are tremendous when scientists of varying disciplines work together on a similar goal, and in this connected era bringing research communities together through technology can have real and significant impact on scientific discoveries and ultimately patient care."

Pre-populated with over 1.5 million Pub-Med-based expert profiles, BiomedExperts allows scientists and researchers to directly connect with and explore their own professional contacts, grow their networks and identify researchers with the expertise needed for future collaborations. Through user-friendly search interfaces, potential research collaborators can share data and collaborate with professionals from more than 1,800 organizations and institutions from 137 countries, totaling more than 21 million connections made through the site.

"It's exciting to see how this tool is paving the way for researchers to grow their professional networks and connect with professionals in the scientific research community," said Bill Kirkland, CEO of Collexis Holdings, Inc. "And now, with more than 30,000 registered users, we hope the collaborative opportunities will continue to increase rapidly, furthering our mission to provide scientists and researchers with the tools they need to help advance medical science, thereby improving the greater good."

To learn more about Collexis and how BiomedExperts is improving research capabilities, please visit www.collexis.comwww.collexis.com and www.biomedexperts.com.

About Collexis Holdings, Inc.
Collexis Holdings, Inc., a leading developer of semantic search and knowledge discovery software is headquartered in Columbia, South Carolina (USA) with major operations in Cincinnati, Ohio, Geldermalsen, the Netherlands and Cologne, Germany. Collexis now offers the world's first pre-populated scientific social network for life science researchers, www.biomedexperts.com. Collexis’ proprietary technology builds conceptual profiles of text, called Fingerprints, from documents, Websites, emails and other digitized content and matches them with a comprehensive list of pre-defined "fingerprinted" concepts to make research results more relevant and efficient. This matching of concepts eliminates the ambiguity and lack of priority associated with word searches. The results are often described as "finding needles in many haystacks." Through this novel approach, Collexis can build unique applications to search, index and aggregate information as well as prioritize, trend and predict data based on sources in multiple industries without the limitations of language or dialect. Collexis’ current clients in the public, private and academic sectors include the Mayo Clinic; Johns Hopkins University; Dana-Farber Cancer Institute, the University of California, San Francisco; the University of South Carolina; Erasmus University Library; Bristol-Myers Squibb; Lockheed Martin; the World Health Organization; Wellcome Trust; the National Institutes of Health; and the U.S. Department of Defense. Shares of Collexis common stock are traded under the symbol CLXS on the OTC Bulletin Board (OTC BB). For more information, visit www.collexis.com.

Most Popular Now

Johnson & Johnson Announces Submission to Worl…

Johnson & Johnson (NYSE: JNJ) (the Company) announced that Janssen-Cilag International N.V. has submitted for Emergency Use Listing (EUL) to the World Health Organization...

Anticancer drug may improve outcome for severe COV…

Treating severe COVID-19 patients with the anticancer drug bevacizumab may reduce mortality and speed up recovery, according to a small clinical study in Italy and China ...

Pfizer and BioNTech commence global clinical trial…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the first participants have been dosed in a global Phase 2/3 study to further evaluate the saf...

GSK and Vir Biotechnology expand coronavirus colla…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) have signed a binding agreement to expand their existing collaboration to include the resear...

Sanofi to provide manufacturing support to Johnson…

Sanofi has entered into an agreement with Janssen Pharmaceutical NV and Janssen Pharmaceuticals, Inc., two of the Janssen Pharmaceutical Companies of Johnson & Johnson, u...

One dose of COVID-19 vaccine provokes strong immun…

Although clinical trial data are encouraging, real-world evidence with regard to the COVID-19 vaccine remains scarce. In particular, response to the vaccine among those p...

Could a nasal spray prevent coronavirus transmissi…

A nasal antiviral created by researchers at Columbia University Vagelos College of Physicians and Surgeons blocked transmission of SARS-CoV-2 in ferrets, suggesting the n...

European Commission purchases additional 150 milli…

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Commission purchased an...

Sanofi and GSK initiate new Phase 2 study of their…

Sanofi and GlaxoSmithKline (GSK) announced the initiation of a new Phase 2 study with 720 volunteers aged 18 and over to select the most appropriate antigen dosage for Ph...

CureVac initiates rolling submission with European…

CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today annou...

Neandertal gene variants both increase and decreas…

Last year, researchers at Karolinska Institutet in Sweden and the Max Planck Institute for Evolutionary Anthropology in Leipzig, Germany showed that a major genetic risk ...

Pfizer and BioNTech publish data from in vitro stu…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the publication in Nature Medicine of data from in vitro studies that demonstrate that sera from in...